Eyenovia To Report Third Quarter 2020 Results
NewsNEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will…
Recent Posts
- Eyenovia Announces Independent Director Stephen Benjamin To Step Down To Assume Role Of Head Of White House’s Office Of Public Engagement March 2, 2023
- Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals February 15, 2023
- Eyenovia Reveals Positive Evidence that Optejet® Delivery Technology Decreased Inflammation from Preserved Glaucoma Solutions Compared to Drops January 13, 2023
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com